Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Expert Review of Hematology

• Publication date

  2018-03-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/17474086.2018.1456331PMID 29582696
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biological Background of Resistance to Current Standards of Care in Multiple Myeloma

  2019cited by this paper
• CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance

  2018cited by this paper
• Blood Transfusion Management and Transfusion‐Related Outcomes in Daratumumab‐Treated Patients With Relapsed or Refractory Multiple Myeloma

  2018cited by this paper
• Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

  2018influential reference
• Inhibition of HIF1α-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy

  2018cited by this paper
• Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study

  2017cited by this paper
• Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159

  2017cited by this paper
• Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma

  2017cited by this paper
• Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.

  2017cited by this paper
• A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.

  2017cited by this paper
• Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

  2017influential reference
• Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth

  2017influential reference
• Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison

  2017cited by this paper
• Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan

  2017cited by this paper
• Functional evidence that progenitor cells near sites of inflammation are precursors for aggressive prostate cancer

  2017cited by this paper
• Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy

  2017cited by this paper
• Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

  2017cited by this paper
• Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux

  2017cited by this paper
• Daratumumab, Bortezomib, and Dexamethasone (DVd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Castor

  2017cited by this paper
• Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple Myeloma

  2017cited by this paper
• Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study

  2017influential reference
• Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

  2016influential reference
• PHARMACODYNAMIC RELATIONSHIP BETWEEN NATURAL KILLER CELLS AND DARATUMUMAB EXPOSURE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

  2016cited by this paper
• New mAb therapies in multiple myeloma: interference with blood transfusion compatibility testing

  2016cited by this paper
• Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux

  2016cited by this paper
• CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.

  2016cited by this paper
• A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma

  2016cited by this paper
• Clinical ef fi cacy and management of monoclonal antibodies targeting CD 38 and SLAMF 7 in multiple myeloma

  2016cited by this paper
• Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.

  2016influential reference
• Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

  2016cited by this paper
• Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

  2016cited by this paper
• Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor

  2016cited by this paper
• Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

  2016influential reference
• Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.

  2016cited by this paper
• Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma

  2016cited by this paper
• Overcoming the Interference of Daratumumab with Immunofixation Electrophoresis (IFE) Using an Industry-Developed Dira Test : Hydrashift 2/4 Daratumumab

  2016cited by this paper
• Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

  2016influential reference
• Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.

  2016influential reference
• When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy

  2015cited by this paper
• Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab

  2015cited by this paper
• PDL 1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD 1-PDL 1 Therapy

  2015cited by this paper
• Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

  2015cited by this paper
• Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study

  2015cited by this paper
• Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.

  2015cited by this paper
• Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

  2015cited by this paper
• PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy

  2015cited by this paper
• Resolving the daratumumab interference with blood compatibility testing

  2015cited by this paper
• CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon

  2015cited by this paper
• Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

  2015influential reference
• Transfusion management of patients receiving daratumumab therapy for advanced plasma cell myeloma

  2015cited by this paper
• A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM).

  2015cited by this paper
• Elotuzumab: serum protein electrophoresis and immunofixation interference with clinical assessment of M-protein response in relapsed/refractory multiple myeloma (RRMM)

  2015cited by this paper
• A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma

  2015cited by this paper
• Treatment of Ex Vivo Expanded NK Cells with Daratumumab F(ab')2 Fragments Protects Adoptively Transferred NK Cells from Daratumumab-Mediated Killing and Augments Daratumumab-Induced Antibody Dependent Cellular Toxicity (ADCC) of Myeloma

  2015cited by this paper
• Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.

  2015influential reference
• International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

  2014cited by this paper
• Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79

  2014influential reference
• Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.

  2014cited by this paper
• CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma.

  2013cited by this paper
• Lenalidomide and dexamethasone for multiple myeloma

  2013cited by this paper
• ELOQUENT-1: A phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006).

  2012cited by this paper
• Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.

  2012cited by this paper
• A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

  2012cited by this paper
• A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.

  2012cited by this paper
• Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

  2012cited by this paper
• CD38 and chronic lymphocytic leukemia: a decade later.

  2011cited by this paper
• The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies

  2011influential reference
• Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease.

  2010cited by this paper
• Effect of Elotuzumab on Circulating Lymphocytes, Chemokines, and Cytokines In Multiple Myeloma Patients

  2010cited by this paper
• Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function

  2009cited by this paper
• CD38 and CD157 Ectoenzymes Mark Cell Subsets in the Human Corneal Limbus

  2009cited by this paper
• Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.

  2008influential reference
• Improved survival in multiple myeloma and the impact of novel therapies.

  2008cited by this paper
• CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

  2008cited by this paper
• CS 1 , a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

  2008cited by this paper
• Methodologic advancements in the study of airway smooth muscle.

  2004cited by this paper
• CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function.

  2002cited by this paper
• Treatment of a patient with end‐stage renal disease with Rituximab: Pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis

  2002cited by this paper
• Cutting Edge: Activation of NK Cell-Mediated Cytotoxicity by a SAP-Independent Receptor of the CD2 Family1

  2001cited by this paper
• The blood.

  1977cited by this paper

• Bioinformatics analysis of intrinsic drivers of immune dysregulation in multiple myeloma to elucidate immune phenotypes and discover prognostic gene signatures

  2025cites this paper
• Targets for CAR Therapy in Multiple Myeloma

  2025cites this paper
• Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging

  2023influential citation
• SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments

  2023cites this paper
• SLAMF7 regulates the inflammatory response in macrophages during polymicrobial sepsis

  2023cites this paper
• Library-based lead compound discovery for CS-1 protein in multiple myeloma: homology modelling, molecular dynamic simulations, virtual screening and molecular docking

  2021cites this paper
• Chimeric antigen receptor T‐cells, bispecific antibodies, and antibody‐drug conjugates for multiple myeloma: An update

  2021cites this paper
• Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy

  2021cites this paper
• Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma

  2020cites this paper
• Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses

  2020cites this paper
• Monoclonal antibodies in newly diagnosed and smoldering multiple myeloma: an updated review of current clinical evidence

  2020cites this paper
• ImmunoPET in Multiple Myeloma—What? So What? Now What?

  2020influential citation
• Modern Treatments and Future Directions for Relapsed/Refractory Multiple Myeloma Patients.

  2020cites this paper
• CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism

  2020cites this paper
• A Review of Interstitial Pneumonitis Caused by Elotuzumab Through Case Discussions and Academic Writings

  2020influential citation
• Anti-body building: The exercise of advancing immune based myeloma therapies.

  2020cites this paper
• Biological Background of Resistance to Current Standards of Care in Multiple Myeloma

  2019cites this paper
• Biology and therapy of multiple myeloma

  2019cites this paper
• Inhibition of HIF1α-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy

  2018cites this paper
• Etude de l'implication de mécanismes épigénétiques dans la physiopathologie du myélome multiple et dans la différenciation plasmocytaire normale

  2018cites this paper
• CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance

  2018cites this paper